FDAnews
www.fdanews.com/articles/80788-indevus-initiates-phase-iii-clinical-program-for-sanctura-xr-in-overactive-bladder

INDEVUS INITIATES PHASE III CLINICAL PROGRAM FOR SANCTURA XR IN OVERACTIVE BLADDER

September 9, 2005

Indevus Pharmaceuticals has initiated a Phase III clinical program for Sanctura XR in patients with overactive bladder. Sanctura XR is the once-daily formulation of Sanctura, which is currently being marketed in the U.S.

The program consists of two 12-week, double-blind, placebo-controlled studies totaling 1,200 adults at approximately 120 sites in the U.S. The objective of the trials is to evaluate the effects of once-daily dosing of trospium chloride on urinary frequency, urge incontinence and other related symptoms associated with overactive bladder.